Brain tumor BBB technology applications — the focused ultrasound, drug-eluting wafers, convection-enhanced delivery, and polymer-based local delivery systems addressing the BBB challenge in glioblastoma and brain metastasis treatment — create important commercial applications, with the Blood Brain Barrier Technologies Market reflecting brain tumor treatment as a commercially significant BBB technology market.

Glioblastoma drug delivery challenge — the GBM's heterogeneous BBB disruption (tumor core has disrupted BBB, infiltrating edge has intact BBB) creating the complex delivery landscape where enhancing BBB crossing may most benefit the infiltrating tumor cells that cause recurrence. The FDA-approved Gliadel carmustine wafer demonstrating the local drug delivery approach achieving better tumor exposure than systemic IV delivery.

Focused ultrasound for GBM chemotherapy enhancement — the clinical trials investigating FUS BBB opening to enhance chemotherapy (temozolomide, carboplatin) delivery to GBM — create the FUS brain tumor commercial application. The CarThera SonoCloud implantable ultrasound device enabling repeated ultrasound BBB opening sessions in GBM patients without external positioning demonstrating the innovative GBM-specific FUS delivery approach.

Convection-enhanced delivery (CED) — the direct intracerebral infusion of drugs through stereotactically placed catheters creating pressure gradient drug distribution through brain parenchyma — represents the invasive but high-concentration local delivery approach. Pediatric DIPG (diffuse intrinsic pontine glioma) CED clinical trials creating the most active CED development program from this universally fatal pediatric brain tumor's desperate unmet need.

Do you think the combination of checkpoint immunotherapy delivered via BBB-opening technology will eventually achieve meaningful response rates in glioblastoma, transforming an incurable disease into a manageable chronic condition?

FAQ

What is the CarThera SonoCloud for GBM treatment? SonoCloud (CarThera): implantable ultrasound device for brain tumors; placed surgically (one centimeter diameter, bone-anchored); generates low-intensity ultrasound pulses during IV chemotherapy infusions; creates repeated BBB opening sessions without need for external FUS device positioning; advantage for GBM: patients can receive multiple sessions easily; Phase I/II trial completed: enhanced permeability confirmed; combined with carboplatin in recurrent GBM; Phase II ongoing; carvedilol Phase II: enhanced temozolomide delivery; commercial: requires surgical implantation (combining with debulking surgery); FDA IDE approved for trials; French regulatory approval for investigational use; potential first commercially available implantable BBB opening device.

What is convection-enhanced delivery and when is it used for brain tumors? CED (convection-enhanced delivery): stereotactic catheter implantation into brain parenchyma; continuous infusion creates positive pressure gradient distributing drug through interstitial space; bypasses BBB entirely; achieves high local drug concentrations; applications: pediatric DIPG (brainstem tumor — systemic delivery impossible); GBM local recurrence; clinical trials: DIPG CED with ONC201 (dopamine receptor antagonist), panobinostat, gemcitabine; advantages: no BBB crossing needed; high local concentration; limitations: invasive (craniotomy or stereotactic procedure); uneven distribution in heterogeneous tumor; catheter track damage; commercial: specialized procedure at academic centers; limited commercial products; primarily research use.

#BloodBrainBarrier #GlioblastomaBBB #BrainTumorDelivery #SonoCloud #CED #DIPGtreatment